MAM
PRME icon

Milestone Asset Management’s Prime Medicine PRME Stock Holding History

Milestone Asset Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$369K Buy
+100,035
New +$332K 0.06% 209

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Milestone Asset Management's PRME Position: Q2 2026 in Review

Milestone Asset Management opened a new position in Prime Medicine (PRME) in Q2 2026: 100,035 shares worth $369K. The stake represents 0.06% of the portfolio and ranks #209 among its holdings.

187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Milestone Asset Management held 100,035 shares of Prime Medicine worth $369K as of Q2 2026.
  • Prime Medicine was a new Milestone Asset Management position in Q2 2026.
  • Prime Medicine made up 0.06% of Milestone Asset Management's portfolio in Q2 2026, its #209 holding.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Milestone Asset Management's 13F filing for Q2 2026, filed 15 Jul 2026.